Narrative approaches to treat hypertension: Emerging therapeutic perspectives

Muhammad Saleem, Amna Batool, Umme Habiba Hasan, Umer Maqsood, Farha Abid


DOI: http://dx.doi.org/10.22200/pjpr.2017148-58

Abstract


Various pathophysiologic facets contribute to the pathogenesis of hypertension and are root causes of cardiovascular diseases with end-organ damage. Seeing that, renin angiotensin pathway along with sympathetic nervous system are predominantly involved in HTN development and recently targeted with conventional antihypertensive therapies including diuretics, b-blockers, and calcium channel blockers,  renin–angiotensin–aldosterone system antagonists with erratic results. Although current therapeutic modalities target these contributory factors but still not effectual in the apt management of blood pressure in many populations thus pointing towards the inevitability of newer pharmacological as well as non-pharmacological approaches to not only manage but cure this perplexing disorder. Aldosterone synthase inhibitor, selective aldosterone receptor antagonist, prorenin inhibitor and vasopeptidase inhibitor in company with other complementary alternatives consisting of vaccine based strategies, gene based therapeutics (targeting both vasodilatory genes along with vasoconstrictor genes), fine-tuning of endothelium-mediated responses and device base interventions including baroreflex sensitization and renal sympathetic denervation may lead to more effective , curative or preventive employment against CVS diseases. Hence, these narrative approaches in HTN therapeutics are although slow in progress but intriguing area which in future might be more beneficial in the treatment and management of hypertension in majority of populace with minimum risks.

Key words: Hypertension, Innovative targets, Renin, Aldosteron, Genetic target


Full Text:

PDF

References


Ambühl PM, Tissot AC, Fulurija A, Maurer P, Nussberger J, Sabat R & Pfister T. (2007). A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity. J Hypertens., 25: 63-72.

Bakris GL, Lindholm LH, Black HR, Krum H, Linas S, Linseman JV and Weber M. (2010). Divergent results using clinic and ambulatory blood pressures report of a darusentan-resistant hypertension trial. Hypertension., 56: 824-830.

Corti R, Burnett JC, Rouleau JL, Ruschitzka F and Lüscher TF. (2001). Vasopeptidase Inhibitors A New Therapeutic Concept in Cardiovascular Disease? Circulation., 104:1856-1862.

Corti R, Burnett JC, Rouleau JL, Ruschitzka F and Lüscher TF. (2001). Vasopeptidase Inhibitors A New Therapeutic Concept in Cardiovascular Disease?. Circulation., 104: 1856-1862.

Danser, A. J., & Deinum, J. (2005). Renin, prorenin and the putative (pro) renin receptor. Hypertension., 46: 1069-1076

Dibona GF. (2003). Neural control of the kidney past, present, and future. Hypertension., 41: 621-624.

Dietz JD, Du S, Bolten CW, Payne MA, Xia C, Blinn JR and Hu X. (2008). A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity. Hypertension., 51: 742-748.

Divya S, Bhavya N, Kumar KP, Keerthi KS and Dhanaraju MD. (2011). New Era of Antihypertensive Agents-Vasopeptidase Inhibitors. World J Med Sci., 6:193-201.

Feldstein C and Romero C. (2007). Role of endothelins in hypertension. Am J ther., 14: 147-153.

Félétou M, Köhler R and Vanhoutte PM. (2010). Endothelium-derived vasoactive factors and hypertension: possible roles in pathogenesis and as treatment targets. Curr hypertens rep., 12: 267-275.

Fiebeler A, Nussberger J, Shagdarsuren E, Rong S, Hilfenhaus G, Al-Saadi N and Jeng, AY. (2005). Aldosterone synthase inhibitor ameliorates angiotensin II–induced organ damage. Circulation., 111: 3087-3094.

Förstermann U and Münzel T. (2006). Endothelial nitric oxide synthase in vascular disease from marvel to menace. Circulation., 113:1708-1714.

Hargovan M and Ferro A. (2014). Aldosterone synthase inhibitors in hypertension: current status and future possibilities. JRSM cardiovascular disease., 3: 2048004014522440.

Katovich MJ, Grobe JL and Raizada MK. (2005). Current and Future Novel Targets of Gene Therapy for Hypertension. In Cardiovascular Genomics. Pp: 213-246. Humana Press.

Katovich MJ, Grobe JL, Huentelman M and Raizada MK. (2005). Angiotensin‐converting enzyme 2 as a novel target for gene therapy for hypertension. Exp. Physiol., 90: 299-305.

Kaur, M, Rana AC and Kumar, S. (2011). Induction of hypertension by various animal models. Int. J. Pharm. Biol. Sci.,1: 335-340

Krum H, Sobotka P, Mahfoud F, Böhm M, Esler M and Schlaich M. (2011). Device-Based Antihypertensive Therapy Therapeutic Modulation of the Autonomic Nervous System. Circulation., 123: 209-215.

Mancia G and Grassi G. (2014). The autonomic nervous system and hypertension. Circ Res., 114: 1804-1814

Mancia G, Grassi G, Giannattasio C and Seravalle G. (1999). Sympathetic activation in the pathogenesis of hypertension and progression of organ damage. Hypertension., 34: 724-728.

Michel JB, Sayah S, Guettier C, Nussberger J, Philippe M, Gonzalez MF and Corvol P. (1990). Physiological and immunopathological consequences of active immunization of spontaneously hypertensive and normotensive rats against murine renin. Circulation., 81: 1899-1910.

Morris BJ. (1989). Human renin protein and gene structures: present and future targets for renin blockade in treatment of hypertension. J Hypertens., 7: S9-S14.

Nguyen G and Muller DN. (2010). The biology of the (pro) renin receptor. J Am Soc Nephrol., 21: 18-23.

Oparil S, Zaman MA and Calhoun DA. (2003). Pathogenesis of hypertension. Ann. Intern. Med., 139: 761-776

Pachori AS, Huentelman MJ, Francis SC, Gelband CH, Katovich MJ and Raizada MK. (2001). The future of hypertension therapy: Sense, antisense, or nonsense?. Hypertension., 37 :357-364.

Potthoff SA, Rump LC and Vonend O. (2011). Novel Approaches in Hypertension Treatment-Modulation of the Sympathetic Overactivity. INTECH Open Access Publisher.

Sica D, Bakris G, Bisognano J, Nadim M, Sanchez L. ( 2010). For the Rheos Pivotal Trial Investigators. A phase III trial of baroreflex activation therapy for resistant hypertension: trial design and baseline characteristics in the Rheos Pivotal Trial. J Clin Hypertens .,12: A114.

Sica DA. (2008). Endothelin Receptor Antagonism. What Does the Future Hold?. Hypertension., 52:460-461

Sievert H. (2010). Symplicity HTN-1: 18-month results of sympathetic renal denervation in resistant hypertension. Euro-PCR.

Unger T, Paulis L and Sica DA. (2011). Therapeutic perspectives in hypertension: novel means for renin–angiotensin–aldosterone system modulation and emerging device-based approaches. Eur heart J., 32: 2739-2747.

Vanhoutte PM and Tang EH. (2008). Endothelium‐dependent contractions: when a good guy turns bad! J Physiol., 586: 5295-5304.

Weber MA. (2001). Vasopeptidase inhibitors. Lancet., 358: 1525-1532.

Weber MA, Black H, Bakris G, Krum H, Linas S, Weiss R. and Lindholm LH. (2009). A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial. Lancet., 374:1423-1431.

White WB, Calhoun DA, Krum H, Guo W, Trapani AJ, Lefkowitz M and Menard J. (2010). Blockade of aldosterone production as a novel approach to the management of high blood pressure: efficacy and tolerability of the aldosterone synthase inhibitor LCI699 in patients with stage 1-2 hypertension. J Am Coll Cardiol., 55: A61-E582.

Lifton RP, Gharavi AG and Geller DS. (2001). Molecular mechanisms of human hypertension. Cell., 104: 545-556.

Carretero OA and Oparil S. (2000). Essential hypertension part I: definition and etiology. Circulation., 101: 329-335

.

Paulis L and Unger T. (2010). Novel therapeutic targets for hypertension. Nat Rev Cardiol., 7: 431-441.

Fyhrquist F and Saijonma O. (2008). Renin‐angiotensin system revisited. J intern med., 264: 224-236.

Foëx P and Sear JW. (2004). Hypertension: pathophysiology and treatment. Continuing education in anaesthesia, critical care & pain., 4: 71-75




DOI: http://dx.doi.org/10.22200/pjpr.2017148-58

Refbacks

  • There are currently no refbacks.


Copyright (c) 2017 Pakistan Journal of Pharmaceutical Research

Copyright © 2014 All Rights Reserved  Pakistan Journal of Pharmaceutical Research 
Powered by Department of Pharmacy BZU | Designed By: Muqeet Wahid